Overview
- Federal Judge Sebastián Casanello denied prosecutor Franco Picardi’s request to detain former ANDIS director Diego Spagnuolo and kept his interrogation scheduled for Wednesday.
- ANDIS records provided to La Nación show about 48.6 billion pesos in orders of payment to Génesis, Profarma, Floresta and New Farma between December 2023 and October 14, 2025.
- In 21 restricted tenders, Profarma and Génesis received 93.11% of awards worth roughly 30.3 billion pesos, while New Farma and Floresta acted as front bidders to simulate competition, according to the prosecutor.
- Price comparisons cited by the filing include Macitentan sold at about 411,764 pesos in an open bid versus up to 8.29 million in restricted buys, and Burosumab at around 21 million in open processes versus 39–45 million in closed ones.
- The case file outlines a coordinated network of officials and para‑statals supported by chats, seized notebooks and security video, and it alleges a Roche employee accessed the SIIPFIS system with credentials from an ANDIS official.